Trial Information

Summary: Hypertension Study CSPP100A2411

Novartis is conducting this clinical research trial to find out if the drug aliskiren hydrochlorothiazide (TekturnaŽ HCT) compared to hydrochlorothiazide (HCTZ) alone is safe and will effectively lower blood pressure. Patients must be 55 years or older and have stage 2 systolic high blood pressure (systolic blood pressure greater than or equal to 160 mm Hg or less than 200 mm Hg). Both the combination of aliskiren hydrochlorothiazide and hydrochlorothiazide alone are approved by the US Food and Drug Administration (FDA) and are available for sale in the U.S.

Participants will be required to visit the study center a maximum of 9 times over a duration of 12 weeks. Each visit will take about 1-2 hours.
www.NovartisClinicalTrials.com

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: November 19, 2008 at 2:55:53 PM